Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Moosmann

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
MMW Fortschritte Der Medizin|October 20, 2007
[Neoadjuvant and adjuvant therapies for solid tumours]Volker Heinemann, Nicolas Moosmann
Expert Opinion on Biological Therapy|January 26, 2007
Cetuximab in the treatment of metastatic colorectal cancerNicolas Moosmann, Volker Heinemann
Clinical Colorectal Cancer|May 27, 2008
Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancerNicolas Moosmann, Volker Heinemann
Expert Review of Anticancer Therapy|March 28, 2008
Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancerNicolas Moosmann, Volker Heinemann
Experimental Dermatology|May 28, 2008
A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibitionAndreas Wollenberg, Nicolas Moosmann, Elisabeth Klein, et al.
World Journal of Gastroenterology|December 29, 2016
"<i>En bloc</i>" caudate lobe and inferior vena cava resection following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal and liver metastasis of colorectal cancerPatricia Sánchez-Velázquez, Nicolas Moosmann, Ingolf Töpel, et al.
In Vivo (Athens, Greece)|September 3, 2004
Differential role of extra- and intracellular superoxide anions for nitric oxide-mediated apoptosis inductionMareike Steinmann, Nicolas Moosmann, Mareike Schimmel, et al.
Onkologie|September 25, 2007
Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemiaNicolas Moosmann, Dorit Laessig, Henrik Jakob Michaely, et al.
Deutsches Arzteblatt International|May 28, 2009
The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR statusSebastian Stintzing, Volker Heinemann, Nicolas Moosmann, et al.
Oncology|April 22, 2008
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancerStefan Boeck, Ralf Wilkowski, Christiane J Bruns, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
MMW Fortschritte Der Medizin|October 20, 2007
[Neoadjuvant and adjuvant therapies for solid tumours]Volker Heinemann, Nicolas Moosmann
Expert Opinion on Biological Therapy|January 26, 2007
Cetuximab in the treatment of metastatic colorectal cancerNicolas Moosmann, Volker Heinemann
Clinical Colorectal Cancer|May 27, 2008
Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancerNicolas Moosmann, Volker Heinemann
Expert Review of Anticancer Therapy|March 28, 2008
Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancerNicolas Moosmann, Volker Heinemann
Experimental Dermatology|May 28, 2008
A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibitionAndreas Wollenberg, Nicolas Moosmann, Elisabeth Klein, et al.
World Journal of Gastroenterology|December 29, 2016
"<i>En bloc</i>" caudate lobe and inferior vena cava resection following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal and liver metastasis of colorectal cancerPatricia Sánchez-Velázquez, Nicolas Moosmann, Ingolf Töpel, et al.
In Vivo (Athens, Greece)|September 3, 2004
Differential role of extra- and intracellular superoxide anions for nitric oxide-mediated apoptosis inductionMareike Steinmann, Nicolas Moosmann, Mareike Schimmel, et al.
Onkologie|September 25, 2007
Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemiaNicolas Moosmann, Dorit Laessig, Henrik Jakob Michaely, et al.
Deutsches Arzteblatt International|May 28, 2009
The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR statusSebastian Stintzing, Volker Heinemann, Nicolas Moosmann, et al.
Oncology|April 22, 2008
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancerStefan Boeck, Ralf Wilkowski, Christiane J Bruns, et al.
Pageof 3